Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | PI4KA | P42356 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.40 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.40 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.40 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29877869 | 1.00 | CYP2C19 (0.45) | CYP2C19CYP1A2TSHRYTHDC1TP53 | |
| SCHEMBL12068396 | 0.96 | CYP2C19 (0.43) | CYP2C19CYP1A2TSHRYTHDC1TP53 | |
| SCHEMBL5724445 | 0.86 | CYP1A2 (0.50) | CYP2C19CYP1A2TSHRYTHDC1TP53 | |
| SCHEMBL17847271 | 0.86 | PI4KA (0.46) | CYP2C19CYP1A2TSHRYTHDC1TP53 | |
| SCHEMBL6664608 | 0.85 | ADORA3 (0.47) | CYP2C19CYP1A2TSHRYTHDC1TP53 | |
| SCHEMBL29877816 | 0.84 | CYP2C19 (0.43) | CYP2C19CYP1A2TSHRYTHDC1TP53 | |
| SCHEMBL22411531 | 0.82 | YTHDC1 (0.46) | CYP2C19CYP1A2TSHRYTHDC1MEN1 | |
| SCHEMBL5724119 | 0.81 | CYP1A2 (0.44) | CYP2C19CYP1A2TSHRYTHDC1TP53 | |
| SCHEMBL21685107 | 0.81 | CYP1A2 (0.44) | CYP2C19CYP1A2TSHRYTHDC1TP53 | |
| SCHEMBL21685746 | 0.81 | CYP1A2 (0.42) | CYP2C19CYP1A2TSHRYTHDC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219460-B1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA INC (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20250011324-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC., | 2025-01-09 | — | — | US | disclosed |
| US-12152026-B2 | Transglutaminase 2 (TG2) inhibitors | SITARI PHARMA, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| US-20240317752-A1 | 6-SUBSTITUTED-9H-PURINE DERIVATIVES AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2024-09-26 | — | — | US | disclosed |
| EP-4219460-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | Sitari Pharma, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4219460-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | Sitari Pharma, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11548892-B1 | Transglutaminase 2 (TG2) inhibitors | SITARI PHARMA, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| WO-2022178256-A1 | 6-SUBSTITUTED-9H-PURINE DERIVATIVES AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2022-08-25 | — | — | WO | disclosed |
| EP-3833348-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC (US) | 2021-06-16 | — | — | EP | disclosed |
| US-20210163480-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC. | 2021-06-03 | — | — | US | disclosed |
| EP-2780341-B1 | KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2019-02-13 | — | — | EP | disclosed |
| US-9550781-B2 | Kinase modulating compounds, compositions containing the same and use thereof | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2017-01-24 | — | — | US | disclosed |
| US-9550781-B2 | Kinase modulating compounds, compositions containing the same and use thereof | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2017-01-24 | — | — | US | disclosed |
| US-9550781-B2 | Kinase modulating compounds, compositions containing the same and use thereof | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2017-01-24 | — | — | US | disclosed |
| US-20140296261-A1 | KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2014-10-02 | — | — | US | disclosed |
| US-20140296261-A1 | KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2014-10-02 | — | — | US | disclosed |
| US-20140296261-A1 | KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2014-10-02 | — | — | US | disclosed |
| EP-2780341-A1 | KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | Centaurus Biopharma Co., Ltd. (CN) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013071865-A1 | KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013071865-A1 | KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163480-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | TGM2, TGM3, TGM1 | CYP2C19 3273/4885CYP1A2 3246/4885TSHR 2931/4885 |
| US-20140296261-A1 | KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | MAP3K20, MAP3K1, PRKCH | CYP2C19 4619/4885CYP1A2 4335/4885TSHR 3843/4885 |
| US-11548892-B1 | Transglutaminase 2 (TG2) inhibitors | TGM2, TGM3, TGM1 | CYP2C19 3273/4885CYP1A2 3246/4885TSHR 2931/4885 |
| US-12152026-B2 | Transglutaminase 2 (TG2) inhibitors | TGM2, TGM3, TGM1 | CYP2C19 3273/4885CYP1A2 3246/4885TSHR 2931/4885 |
| US-20250011324-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | TGM2, TGM3, TGM1 | CYP2C19 3273/4885CYP1A2 3246/4885TSHR 2931/4885 |
| US-20240317752-A1 | 6-SUBSTITUTED-9H-PURINE DERIVATIVES AND RELATED USES | TYMP, DPYD, PNP | CYP2C19 195/4885CYP1A2 411/4885TSHR 3688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.